Allogene Therapeutics, Inc. (ALLO - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 62.6% in the past one-month time frame.
The company has seen eight positive estimate revisions in the past month, while its Zacks Consensus Estimate for the current quarter has also moved higher in the same time frame, suggesting that more solid trading could be ahead for Allogene Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Allogene Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.
Another stock worth considering in the Medical – Biomedical and Genetics industry is Abeona Therapeutics Inc. (ABEO - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>